Larimar Therapeutics (LRMR) Total Liabilities (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Total Liabilities for 14 consecutive years, with $37.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 25.84% year-over-year to $37.9 million; the trailing twelve-month figure through Jun 2026 stood at $37.9 million (up 25.84% YoY), and the FY2025 full-year result was $67.8 million, up 138.47% from the prior year.
• Total Liabilities retreated to $37.9 million in Q2 2026 per LRMR's latest filing, from $67.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $67.8 million in Q4 2025 and bottomed at $11.2 million in Q3 2023.
• Historically, Total Liabilities has averaged $24.1 million across 5 years, with a median of $17.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities slipped 21.69% in 2023, then jumped 138.47% in 2025.
• Over 5 years, Total Liabilities stood at $15.5 million in 2022, then decreased by 8.3% to $14.2 million in 2023, then jumped by 99.88% to $28.4 million in 2024, then soared by 138.47% to $67.8 million in 2025, then plunged by 44.04% to $37.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $37.9 million, $67.8 million, and $48.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.